Pharmacy news and alerts

This page provides pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.

Six companies to launch generic versions of Cymbalta

Generic versions of Cymbalta approved in Dec. 2013

(279 KB) Download PDF
Six companies to launch generic versions of Cymbalta

Recall notice for Nova Max® blood glucose test strips

A recall of Nova Max blood glucose test strips was effective July 26, 2013.

(56 KB) Download PDF

Two companies to launch generic versions of Suboxone
The U.S. Food and Drug Administration (FDA) approved Actavis' and Amneal Pharmaceuticals' generic versions of Suboxone sublingual tablets (buprenorphine and naloxone) on Feb. 22, 2013.

Buprenorphine and naloxone sublingual dosage forms are indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine is a partial opioid receptor agonist that reduces the opioid craving and withdrawal symptoms caused by stopping other opiates.

Buprenorphine and naloxone tablets will be considered nonformulary for the Medicare Preferred, National 4 and National 5 formularies. They will be placed in the nonpreferred brand tier for Medicare Plus-5, Select and Commercial Rx4. The product will be placed in the generic tier for the Medicare Puerto Rico, Group Medicare and Commercial Rx3 formularies.

This drug will require prior authorization.

For specific information about formulary coverage of this drug, use Humana's Drug List search tool.